Bone Biologics Corp (BBLG): Price and Financial Metrics

Bone Biologics Corp (BBLG): $1.56

0.10 (+6.85%)

POWR Rating

Component Grades








BBLG Price/Volume Stats

Current price $1.56 52-week high $43.49
Prev. close $1.46 52-week low $1.38
Day low $1.49 Volume 321,905
Day high $1.84 Avg. volume 98,201
50-day MA $1.69 Dividend yield N/A
200-day MA $3.40 Market Cap 1.72M

BBLG Stock Price Chart Interactive Chart >

Bone Biologics Corp (BBLG) Company Bio

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

BBLG Latest News Stream

Event/Time News Detail
Loading, please wait...

BBLG Latest Social Stream

Loading social stream, please wait...

View Full BBLG Social Stream

Latest BBLG News From Around the Web

Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.

BBLG Announces Split as Pursuit of Breakthrough Treatment Continues

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT There are approximately 350,000 spinal fusion surgeries done in the US every year with varying degrees of success in alleviating often debilitating back pain. The existing dominant technology, known as rhBMP, has been quite successful in advancing the spinal fusion procedure but there are also challenges that can come along with

Yahoo | December 20, 2023

Bone Biologics Announces 1-for-8 Reverse Stock Split

BURLINGTON, Mass., December 18, 2023--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol,

Yahoo | December 18, 2023

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BURLINGTON, Mass., November 20, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063

Yahoo | November 20, 2023

Dear LI Stock Fans, Mark Your Calendars for Dec. 4

Li Auto stock fans are preparing for a major catalyst when the company's shares join the Hang Seng Index starting on Dec.

William White on InvestorPlace | November 17, 2023

Why Is Bone Biologics (BBLG) Stock Down 38% Today?

Bone Biologics stock is falling on Friday as shares of BBLG give up some of the gains they saw during an unexpected rally on Thursday!

William White on InvestorPlace | November 17, 2023

Read More 'BBLG' Stories Here

BBLG Price Returns

1-mo -32.17%
3-mo -33.05%
6-mo -48.55%
1-year -95.04%
3-year N/A
5-year N/A
YTD -65.49%
2023 -91.02%
2022 -94.04%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!